Biodesix Announces Receipt of CLIA Registration Number
Biodesix, Inc., is pleased to announce receipt of a CLIA registration which allows the company to commercially market Veristrat® .
254 Results
Biodesix, Inc., is pleased to announce receipt of a CLIA registration which allows the company to commercially market Veristrat® .
Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University will be presenting data on Veristrat at the 45th Annual Meeting of ASCO.
Biodesix announced that Paul J. Beresford has joined the Company as Vice President, Business Development and Strategic Marketing.
Biodesix announced today that Douglas E. Swan has joined the company as Vice President, Commercial Operations, reporting directly to David Brunel, CEO
Biodesix announced today that the United States Patent and Trademark Office has awarded to the company patent number 7,736,905.
Biodesix announces the U.S. commercial availability of VeriStrat.
Biodesix's Paul Beresford will present at the 2011 Biotech Showcase conference taking place January 10–12th at the Parc 55 Wyndham in San Francisco, CA
Biodesix's CEO, David Brunel, will present at the 2010 Personalized Medicine Partnerships conference, Wednesday, February 24th, at 11:00 a.m. eastern time.
Biodesix announced today that it has completed $10 million in Series B-1 financing round. The financing was led by existing shareholders and board members.
Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, led by existing investors.